AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
178.39
-1.15 (-0.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close179.54
Open180.67
Bid177.44 x 4000
Ask178.78 x 900
Day's range178.20 - 181.54
52-week range166.30 - 210.19
Volume2,987,154
Avg. volume2,831,947
Market cap108.806B
Beta (3Y monthly)0.95
PE ratio (TTM)14.23
EPS (TTM)12.54
Earnings date30 Jul 2019
Forward dividend & yield5.80 (3.25%)
Ex-dividend date2019-05-16
1y target est205.35
Trade prices are not sourced from all markets
  • Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
    Zacks5 days ago

    Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

    Key highlights of the past week include collaborations and other pipeline updates.

  • Motley Fool10 days ago

    What Happened in the Stock Market Today

    On a record day for the major benchmarks, Illumina issued a warning, and Novartis and Amgen reported the failure of an Alzheimer's drug.

  • The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
    Zacks10 days ago

    The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

    The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

  • Amgen & Novartis' Alzheimer Studies End in Another Failure
    Zacks10 days ago

    Amgen & Novartis' Alzheimer Studies End in Another Failure

    Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

  • Why Amgen (AMGN) Could Beat Earnings Estimates Again
    Zacks10 days ago

    Why Amgen (AMGN) Could Beat Earnings Estimates Again

    Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • MarketWatch11 days ago

    Amgen and Novartis drop Alzheimer's-prevention study after patients worsened

    Amgen Inc. and Novartis AG announced Thursday afternoon that they will discontinue a study into a potential Alzheimer's disease prevention therapy after patients in the study showed worsening conditions. "An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function," the companies said in a joint announcement. "The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk." The phase 2/3 study, performed in conjunction with Banner Alzheimer's Institute, was testing the BACE1 inhibitor CNP520, or umibecestat, which is an amyloid-focused drug. Biogen Inc. failed in testing of an amyloid-focused drug earlier this year, leading some to predict that focusing on the sticky protein found in the brain could be a losing route to a drug for the debilitating neurodegenerative disease. "We still believe amyloid plays an important but complex role in Alzheimer's disease," Amgen executive David Reese said in Thursday's announcement. Novartis shares were down 1.5% in after-hours trading Thursday, while Amgen shares were not moving after the announcement.

  • Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates
    Yahoo Finance11 days ago

    Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates

    The drug companies provide rebates to PBMs in exchange for distributing their products.

  • Trump's Order on Kidney Care Lifts These Dialysis Stocks
    Zacks11 days ago

    Trump's Order on Kidney Care Lifts These Dialysis Stocks

    Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.

  • Investing.com11 days ago

    Amgen Falls 3%

    Investing.com - Amgen (NASDAQ:AMGN) fell by 3.30% to trade at $176.27 by 10:44 (14:44 GMT) on Thursday on the NASDAQ exchange.

  • Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
    Zacks12 days ago

    Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

    Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.

  • The 10 Biggest Healthcare Stocks
    Motley Fool12 days ago

    The 10 Biggest Healthcare Stocks

    How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

  • Court Ruling Topples Trump Order, No Price Display in TV Ads
    Zacks12 days ago

    Court Ruling Topples Trump Order, No Price Display in TV Ads

    The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

  • Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
    Zacks12 days ago

    Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA

    FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications

  • Will Patent Woes Boost Pharma Stock Megamergers Further?
    Zacks12 days ago

    Will Patent Woes Boost Pharma Stock Megamergers Further?

    With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

  • Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
    Zacks13 days ago

    Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline

    Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.

  • Here's Why Amgen Stock Gained 10% in June
    Motley Fool16 days ago

    Here's Why Amgen Stock Gained 10% in June

    The biotech's shares perked up for two unrelated reasons last month.

  • Top Analyst Reports: Mastercard, Coca-Cola, Amgen & More
    Zacks18 days ago

    Top Analyst Reports: Mastercard, Coca-Cola, Amgen & More

    Top Analyst Reports: Mastercard, Coca-Cola, Amgen & More

  • Should Amgen Inc. (NASDAQ:AMGN) Be Part Of Your Dividend Portfolio?
    Simply Wall St.18 days ago

    Should Amgen Inc. (NASDAQ:AMGN) Be Part Of Your Dividend Portfolio?

    Could Amgen Inc. (NASDAQ:AMGN) be an attractive dividend share to own for the long haul? Investors are often drawn to...

  • Bloomberg19 days ago

    Biotech Braces for Busy Summer as 2019 M&A Volume Heats Up

    (Bloomberg) -- Investors may be digesting a deal from Bristol-Myers Squibb Co. for Celgene Corp. and getting their teeth into AbbVie Inc.’s bid for Allergan Plc, but there are plenty of other large-cap biotechs and pharma still hungry for action.“Do not sleep on the summer,” Jefferies trading specialist Jared Holz cautioned clients in a note. “Conversations with several banking contacts suggest mergers will not slow down in what are normally seasonally slow months.”Who needs deals? The usual suspects -- large-cap drugmakers with patent cliffs and dwindling pipelines. With the top 20 drugmakers generating over $150 billion a year in free cash flow and facing slowing growth, “there’s high interest from big pharma and big biotech in making acquisitions,” Andy Acker, a lifesciences portfolio manager for Janus Henderson, said in a phone interview.With regards to whether those deals will be mega-mergers or smaller bolt-ons, “anything is possible,” Holz said via phone. Although there aren’t as many targets left as there were six months ago, larger-scale deals are just as likely as smaller ones, he said.He predicts the biggest catalyst for the second half may be a deal that closes before any political changes ahead of the 2020 election. “You want to beat the fundamental shift,” he said.While the number of drug sector deals in 2019 to-date are on pace to match 2018’s total, the volume has exceeded last year’s midpoint thanks to mega-cap deals, according to Bloomberg data.Potential TargetsVertex Pharmaceuticals Inc., Incyte Corp. and Biogen Inc. are seen among the most likely targets for a large deal. Jefferies’ Holz and Cantor Fitzgerald analyst Alethia Young both called Biogen a “wildcard,” as the company could either be a buyer or seller. Other potential acquirers include Eli Lilly & Co., Pfizer Inc., Merck & Co., Sanofi, Novartis AG and Johnson & Johnson, as well as biotechs Gilead Sciences Inc. and Amgen Inc.While large caps launch the bulk of new drugs, more than half of the new medicines approved are developed from small and mid-cap company pipelines, according to Acker. This makes biotech catalysts a key focus for investors looking to own a stock before it gets bought.Still, 90% of new medicines in development never make it to market, Acker cautions, and for those drugs that do win regulatory approval they will still face a commercial risk, especially if they don’t get bought.Jefferies analyst Michael Yee found that the shares of half of all biotechs that didn’t get bought underperformed in the months that followed a new drug launch.Further reading: Slow Start to 2019 M&A Gathers Force With June’s Flood of DealsHighlights from biotech calendars for the second half:Amgen: A court decision or settlement on Amgen’s dispute with Sandoz over patents for its top-selling arthritis drug Enbrel. Analysts predict Amgen shares could move as much as 10%.Amarin Corp.: A Food and Drug Administration decision on Sept. 28 to update the label for the heart pill Vascepa will be “the gatekeeper for M&A,” Roth analyst Yasmeen Rahimi said.AnaptysBio Inc: Investors are waiting for results for etokimab in atopic dermatitis; shares may rise up to 60% on positive results, JPMorgan analyst Anupam Rama predicted last month.Enanta Pharmaceuticals Inc: Initial results from a NASH study expected in the third quarter.Gilead Sciences: Results evaluating NASH combinations expected to readout in the fourth quarter and may determine the biotech’s direction in the liver disease after a recent failure.GlycoMimetics Inc: Results from a study of Pfizer Inc-partnered rivipansel for sickle-cell-related symptoms. Pfizer called out the drug as a potential blockbusterMirati Therapeutics Inc: The stock has been breaking records since results from an Amgen study, viewed as a sign that Mirati’s cancer drug may work even better when the small-cap reveals clinical data.Sage Therapeutics Inc: Results in bipolar disorder patients with major depression will be closely watched by investors.Reata Pharmaceuticals Inc: Data from a study of bardoxolone in patients with Alport syndrome, and another study of omaveloxolone in Friedreich’s ataxia.WaVe Life Sciences Ltd: Two readouts expected for Wave, one in Duchenne muscular dystrophy and another in Huntington’s disease.Vertex: Approval for Vertex’s triple combination pill for cystic fibrosis expected this year, although that could slip into 2020, Young said.\--With assistance from Karen Lin.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Morwenna Coniam, Lisa WolfsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance
    Zacks19 days ago

    Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance

    Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.

  • How to Invest in Biotech Stocks
    Motley Fool20 days ago

    How to Invest in Biotech Stocks

    Seven simple steps to improving your chances of success in this part of the market.

  • Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer
    Zacks21 days ago

    Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer

    Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by the CHMP for triple-negative breast cancer.

  • Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval
    Zacks21 days ago

    Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval

    Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes